Companies
Longping Hi-Tech
8 of 37 GM corn varieties in China's first commercialization batch (21.6% market share); GM corn contribution projected at 250 million yuan net profit in 2026; global leader in hybrid rice.
- Country
- China
- Ticker
- SZSE:000998
SZ:000998
CN
Coverage
| CN | EU | IN | US | |
|---|---|---|---|---|
| crop-biotech | ✓ | ✓ | ✓ | ✓ |
Regulatorsusda-aphisepamoa-chinaefsa
Verifiable facts
| Fact | Value | Source |
|---|---|---|
| Funding | Longping Hi-Tech completed a fixed increase of 1.2 billion yuan (as of 2025). | news.futunn.com |
| Capacity | 900,000+ mu of high-standard seed production bases. | pdf.dfcfw.com |
| Certification | ISO9001 quality management system, China Seed Industry Ten-Year AAA Credit Enterprise, National Crop Seed Industry Leader. | infonotice.sylapp.cn · money.finance.sina.com.cn |
| Regulatory approval | 8 varieties in the first batch of commercialized GM corn; additional GM corn varieties (e.g., Hui Min 380DT, Zhong Yu 303R) completed approval public notice (as of 2026). | infonotice.sylapp.cn · news.futunn.com · farmprogress.com |
| Production site | 60+ breeding test stations globally and 900,000+ mu of high-standard seed production bases in China. | infonotice.sylapp.cn · vip.stock.finance.sina.com.cn · pdf.dfcfw.com |
| Headcount | Approximately 4,220 employees (as of March 2026). | pdf.dfcfw.com · leidacj.com |
| Revenue | 1.71 billion yuan (H1 2026); 8.48 billion yuan (full-year 2025). | infonotice.sylapp.cn · money.finance.sina.com.cn |
Independent sources: farmprogress.com · infonotice.sylapp.cn · leidacj.com · money.finance.sina.com.cn · news.futunn.com · pdf.dfcfw.com · vip.stock.finance.sina.com.cn
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Climate-resilient crops | crop-biotech | Medium | → |
| Precision Plant Breeding & CRISPR Crop Editing | crop-biotech | Low | → |
Compiled by BIOECON from primary sources.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.